Taurine 10 pp 717-727 | Cite as

Effect of Taurine on iNOS-Mediated DNA Damage in Drug-Induced Renal Injury

  • Toshihiro Kato
  • Masahiro Tsunekawa
  • Shumin Wang
  • Takenori Yamashita
  • Ning MaEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 975)


Owing to an outstanding wide antitumor spectrum and excellent anti-tumor effect cisplatin has been used in chemotherapy for malignant tumor. However, cisplatin has strong side effects such as renal injury. Taurine has been found to protect against inflammatory tissue damage in a variety of experimental models. The aim of the present study was to investigate the effect of taurine against iNOS dependent DNA damage in cisplatin-induced renal injury in rats. With the help of a rat model of drug-induced kidney damage, we have assessed the nephrotoxic effects of different doses of cisplatin in the presence and absence of taurine. Immunohistochemical methods were used to examine the distribution of arginine, iNOS, citrulline and 8-nitroguanine in renal tissue. The expression levels of citrulline, iNOS, and 8-nitroguanine immunoreactivities were found to increase as a function of the dose of cisplatin used, and to decrease in the presence of taurine. The expression level of arginine immunoreactivity was reduced as a function of the dose of cisplatin used. On the other hand, iNOS, 8-nitroguanine and citrulline immunohistochemical staining showed an intense immunoreactivity in the renal tubule of cisplatin-treated animals; and arginine immunoreactivity was localized in the renal tubule of taurine-treated animals. We also confirmed the decrease of citrulline and iNOS expression in the renal tubule after taurine administration as well as the expression level of 8-nitroguanine, a nitrative stress marker in the same animals. The present results support the concept that taurine may have a protective role in the formation of cisplatin-related DNA lesions arising through iNOS-mediated nitrative stress.


Cisplatin iNOS Inducible nitric oxide synthase Renal injury 



This work was partly supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.


  1. Barabas K, Milner R, Lurie D, Adin C (2008) Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 6:1–18CrossRefPubMedGoogle Scholar
  2. Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61:223–242CrossRefPubMedGoogle Scholar
  3. Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefPubMedGoogle Scholar
  4. Domitrovic R, Cvijanovic O, Pugel EP, Zagorac GB, Mahmutefendic H, Skoda M (2013) Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology 310:115–123CrossRefPubMedGoogle Scholar
  5. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86:1233–1250CrossRefPubMedGoogle Scholar
  6. Gordon RE, Heller RF (1992) Taurine protection of lungs in hamster models of oxidant injury: a morphologic time study of paraquat and bleomycin treatment. Adv Exp Med Biol 315:319–328CrossRefPubMedGoogle Scholar
  7. Han X, Budreau AM, Chesney RW (2000) The taurine transporter gene and its role in renal development. Amino Acids 19:499–507CrossRefPubMedGoogle Scholar
  8. Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47–61PubMedPubMedCentralGoogle Scholar
  9. Jacobsen JG, Smith LH (1968) Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev 48:424–511PubMedGoogle Scholar
  10. Kato T, Okita S, Wang S, Tsunekawa M, Ma N (2015) The effects of taurine administration against inflammation in heavily exercised skeletal muscle of rats. Adv Exp Med Biol 803:773–784CrossRefPubMedGoogle Scholar
  11. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–584CrossRefPubMedGoogle Scholar
  12. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19–38CrossRefPubMedGoogle Scholar
  13. Kroning R, Lichtenstein AK, Nagami GT (2000) Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 45:43–49CrossRefPubMedGoogle Scholar
  14. Ma N, Aoki E, Semba R (1994) An immunohistochemical study of aspartate, glutamate, and taurine in rat kidney. J Histochem Cytochem 42:621–626CrossRefPubMedGoogle Scholar
  15. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8:10–16CrossRefPubMedPubMedCentralGoogle Scholar
  16. Mozaffari MS, Schaffer SW (2002) Chronic taurine treatment ameliorates reduction in saline-induced diuresis and natriuresis. Kidney Int 61:1750–1759CrossRefPubMedGoogle Scholar
  17. Mozaffari MS, Miyata N, Schaffer SW (2003) Effects of taurine and enalapril on kidney function of the hypertensive glucose-intolerant rat. Am J Hypertens 16:673–680CrossRefPubMedGoogle Scholar
  18. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007CrossRefPubMedGoogle Scholar
  19. Pasantes-Morales H, Cruz C (1985) Taurine: a physiological stabilizer of photoreceptor membranes. Prog Clin Biol Res 179:371–381PubMedGoogle Scholar
  20. Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30:570–581CrossRefPubMedGoogle Scholar
  21. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379CrossRefPubMedGoogle Scholar
  22. Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369CrossRefPubMedGoogle Scholar
  23. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedeberg’s Arch Pharmacol 365:277–283CrossRefGoogle Scholar
  24. Sugiura H, Okita S, Kato T, Naka T, Kawanishi S, Ohnishi S, Oshida Y, Ma N (2013) Protection by taurine against INOS-dependent DNA damage in heavily exercised skeletal muscle by inhibition of the NF-kappaB signaling pathway. Adv Exp Med Biol 775:237–246CrossRefPubMedGoogle Scholar
  25. Thurston JH, Hauhart RE, Dirgo JA (1980) Taurine: a role in osmotic regulation of mammalian brain and possible clinical significance. Life Sci 26:1561–1568CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Toshihiro Kato
    • 1
  • Masahiro Tsunekawa
    • 2
  • Shumin Wang
    • 2
  • Takenori Yamashita
    • 3
  • Ning Ma
    • 2
    Email author
  1. 1.Sport Medical CenterSuzukakaisei HospitalSuzukaJapan
  2. 2.Graduate School of Health ScienceSuzuka University of Medical ScienceSuzukaJapan
  3. 3.Faculty of Health ScienceSuzuka University of Medical ScienceSuzukaJapan

Personalised recommendations